NYSE$DGX
Quest Diagnostics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported a decrease in revenue and EPS due to decline in COVID-19 testing revenue, while base business showed strong growth and full-year guidance was raised.
Quest Diagnostics reported a decrease in first-quarter revenue by 4.0% to $2.61 billion, with a diluted EPS of $2.92, down 15.6% compared to the previous year. However, the base business revenues increased by 6.3%. The company raised its full-year 2022 guidance, expecting a reported diluted EPS between $7.88 and $8.38 and an adjusted diluted EPS between $9.00 and $9.50.
- First quarter revenues decreased by 4.0% to $2.61 billion.
- Reported diluted EPS decreased by 15.6% to $2.92.
- Base business revenues increased by 6.3% to $2.01 billion.
- Full year 2022 reported diluted EPS is now expected to be between $7.88 and $8.38.
Headline financials
Revenue & EPS history
Quest Diagnostics · Revenue · Quarterly
$2.61B
Revenue by segment
Quest Diagnostics · $2.38B total across 1 segment · Q2 2022
- Diagnostic information services$2.38B—100.0%
Forward guidance
The company raises its Full Year 2022 guidance as follows: Net revenues $9.2 billion to $9.5 billion, Base business revenues $8.35 billion to $8.50 billion, COVID-19 testing revenues $0.85 billion to $1.00 billion, Reported diluted EPS $7.88 to $8.38, Adjusted diluted EPS $9.00 to $9.50, Cash provided by operations At least $1.6 billion, Capital expenditures Approximately $400 million.
Tailwinds
- Net revenues are expected to be between $9.2 billion and $9.5 billion.
- Base business revenues are expected to increase by 4.1% to 6.0%.
- COVID-19 testing revenues are expected to be between $0.85 billion and $1.00 billion.
- Reported diluted EPS is expected to be between $7.88 and $8.38.
- Adjusted diluted EPS is expected to be between $9.00 and $9.50.
Headwinds
- Net revenues are expected to decrease by 14.7% to 11.9%.
- COVID-19 testing revenues are expected to decrease by 69.3% to 63.9%.
- Capital expenditures are expected to be approximately $400 million.
- The company's future performance is subject to risks and uncertainties, including the impact of the COVID-19 pandemic.
- Adverse results from pending or future government investigations, lawsuits or private actions could negatively impact the company's financial results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.0%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+2.1%
Avg return
30 days after
45%
33 / 73 earnings
Positive
+11.2%
Q1 2019
Best reaction
-9.9%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.0% | -2.2% | |
| Q4 2025 | +7.4% | +8.2% | +5.0% | |
| Q3 2025 | -3.0% | -4.3% | -1.5% | |
| Q2 2025 | -0.3% | +2.1% | +2.2% | |
| Q1 2025 | +6.8% | +7.4% | +4.8% | |
| Q4 2024 | +5.6% | +5.1% | +11.2% | |
| Q3 2024 | +6.6% | +5.2% | +11.2% | |
| Q2 2024 | -2.3% | -1.2% | +3.7% | |
| Q1 2024 | +5.7% | +3.2% | +7.6% | |
| Q4 2023 | -2.7% | -1.7% | -2.9% | |
| Q3 2023 | +3.3% | +5.1% | +11.8% | |
| Q2 2023 | -7.3% | -6.7% | -8.6% | |
| Q1 2023 | -5.5% | -5.9% | -8.9% | |
| Q4 2022 | -3.9% | -1.8% | -5.3% | |
| Q3 2022 | +8.0% | +13.7% | +15.6% | |
| Q2 2022 | -2.8% | -1.2% | +0.5% | |
| Q1 2022 | -0.9% | -2.7% | +1.9% | |
| Q4 2021 | -1.4% | -1.0% | +1.3% | |
| Q3 2021 | -0.2% | -0.9% | +1.1% | |
| Q2 2021 | +2.7% | +3.1% | +11.9% | |
| Q1 2021 | +0.9% | +1.8% | +1.0% | |
| Q4 2020 | -4.0% | -4.0% | -7.0% | |
| Q3 2020 | +3.5% | +3.5% | +1.6% | |
| Q2 2020 | -3.7% | -4.9% | -9.2% | |
| Q1 2020 | +6.6% | +22.8% | +19.4% | |
| Q4 2019 | +0.0% | +0.5% | -4.2% | |
| Q3 2019 | +0.6% | -1.6% | +2.5% | |
| Q2 2019 | +5.4% | +3.3% | +4.6% | |
| Q1 2019 | +11.2% | +11.9% | +14.6% | |
| Q4 2018 | -2.3% | -2.0% | -1.6% | |
| Q3 2018 | -9.9% | -9.9% | -8.2% | |
| Q2 2018 | -6.3% | -7.1% | -3.6% | |
| Q1 2018 | -2.6% | -1.0% | +1.3% | |
| Q4 2017 | -2.6% | -4.4% | -4.1% | |
| Q3 2017 | +3.3% | +3.5% | +1.1% | |
| Q2 2017 | -1.1% | +0.1% | -2.6% | |
| Q1 2017 | +5.3% | +7.9% | +7.9% | |
| Q4 2016 | +0.9% | +0.0% | +5.9% | |
| Q3 2016 | +0.9% | +0.2% | +3.1% | |
| Q2 2016 | +1.7% | +1.6% | +1.6% | |
| Q1 2016 | +0.8% | — | — | |
| Q4 2015 | -0.1% | — | — | |
| Q3 2015 | -0.3% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -0.6% | — | — | |
| Q4 2014 | +0.7% | — | — | |
| Q3 2014 | +4.2% | — | — | |
| Q2 2014 | +1.4% | — | — | |
| Q1 2014 | -4.2% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | -1.4% | — | — | |
| Q2 2013 | -1.3% | — | — | |
| Q1 2013 | -4.4% | — | — | |
| Q4 2012 | -5.5% | — | — | |
| Q3 2012 | -4.5% | — | — | |
| Q2 2012 | -6.8% | — | — | |
| Q1 2012 | -2.4% | — | — | |
| Q4 2010 | +1.0% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | +0.4% | — | — | |
| Q2 2011 | -2.1% | — | — | |
| Q1 2011 | +0.2% | — | — | |
| Q3 2010 | +0.1% | — | — | |
| Q2 2010 | +1.7% | — | — | |
| Q1 2010 | -2.6% | — | — | |
| Q1 2009 | -2.6% | — | — | |
| Q4 2007 | +1.8% | — | — | |
| Q4 2009 | +1.8% | — | — | |
| Q3 2009 | -0.1% | — | — | |
| Q3 2008 | -0.1% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q4 2008 | -0.6% | — | — | |
| Q2 2008 | -0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro